Nanoenergy in the pharmaceutical field represents a cutting-edge approach that harnesses the unique properties of nanomaterials to revolutionize drug delivery, diagnostics, and therapeutic interventions. The integration of nanotechnology into pharmaceutical research and development has paved the way for more efficient drug formulations and targeted delivery systems. Nano-sized drug carriers, such as liposomes and polymeric nanoparticles, enable precise control over drug release kinetics, enhancing therapeutic efficacy while minimizing side effects. Additionally, nanoscale materials play a crucial role in the development of advanced imaging techniques for early disease detection and monitoring. Nano energy in pharmaceuticals also extends to the design of smart materials that respond to specific physiological cues, further optimizing drug delivery.
This interdisciplinary synergy between nanotechnology and pharmaceuticals holds great promise in overcoming challenges associated with traditional drug delivery, opening new avenues for personalized medicine and improved patient outcomes. As research in this field continues to advance, the potential applications of nano energy in pharmaceuticals are poised to redefine the landscape of medical treatments.
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Analytical strategies for solid-state forms in drug development
Maria Cristina Gamberini, University of Modena e Reggio Emilia, Italy
Title : Understanding drug transport in plasma: The role of protein binding
Saad Tayyab, UCSI University, Malaysia
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Search for novel biomarkers and therapeutic targets for inflammatory disease
Madhav Bhatia, University of Otago, New Zealand
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through de-sign-inspired biotech- & biopharma-driven applications and upgraded business mar-keting to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad AutĂłnoma de Baja California, Mexico
Title : Abuse-deterrent dosage form technique utilizing a fusion of innovative pharmaceuticals and ion exchange resin
Bhupendra Gopalbhai Prajapati, Parul University, India
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia